Stocktoria
PERRIGO Co plc PRGO
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1991-12-17
Chart by TradingView
4/9
Piotroski F — financial health
-0.37
Altman Z″ — distress risk · distress
-11.2%
Dividend payout · safe
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $4.3B | $4.4B | $4.7B | $4.5B | $4.1B |
| Gross profit | $1.5B | $1.5B | $1.7B | $1.5B | $1.4B |
| Operating income | -$1.1B | $112.9M | $151.9M | $78.9M | $410.4M |
| Net income | -$1.4B | -$171.8M | -$12.7M | -$140.6M | -$68.9M |
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M |
| Free cash flow | $145.1M | $244.6M | $303.8M | $210.9M | $4.2M |
| Total assets | $8.5B | $9.6B | $10.8B | $11.0B | $10.4B |
| Total liabilities | $5.6B | $5.3B | $6.0B | $6.2B | $5.3B |
| Shareholders' equity | $2.9B | $4.3B | $4.8B | $4.8B | $5.2B |
| Ratios | |||||
| Gross margin | 35.1% | 35.3% | 36.1% | 32.7% | 34.2% |
| Operating margin | -26.4% | 2.6% | 3.3% | 1.8% | 9.9% |
| Net margin | -33.5% | -3.9% | -0.3% | -3.2% | -1.7% |
| FCF margin | 3.4% | 5.6% | 6.5% | 4.7% | 0.1% |
| Return on assets | -16.7% | -1.8% | -0.1% | -1.3% | -0.7% |
| Return on equity | -48.6% | -4.0% | -0.3% | -2.9% | -1.3% |
| Debt / equity | 1.23× | 0.83× | 0.76× | 0.84× | 0.57× |
| Current ratio | 2.76 | 2.38 | 1.79 | 2.44 | 2.43 |
| Revenue growth | -2.8% | -6.1% | 4.6% | 7.6% | 1.2% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.37 (distress)
- Working capital / assets 0.209
- Retained earnings / assets -0.431
- EBIT / assets -0.131
- Equity / liabilities 0.524
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001585364 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.